Lipid-Lowering Therapy Adherence & Cardiovascular Risk

Summary ⁤of ⁢teh ⁢Research on Lipid-Lowering Therapy (LLT) Adherence and Cardiovascular Outcomes

This research,a systematic review and⁣ meta-analysis by Jones et al. (2025),highlights the significant benefits of adhering to lipid-lowering therapies (LLTs) for patients with atherosclerotic cardiovascular ⁣disease.

key⁢ Findings:

* Adherence Measurement: Most studies used an 80% adherence threshold, with adherence rates ranging from ⁢0.8% to 91.2% in those studies.
* Reduced risk ‍with ≥80% ⁤Adherence: Statistically significant reductions in risk were ‍observed with ≥80% adherence to LLTs, including:
* Death: Hazard Ratio ‍(HR) 0.56 (95% ‍CI, 0.34-0.92; P* = 0.0268)
* Major adverse Cardiovascular Events (MACE): ‍ HR 0.77 (95% CI, 0.68-0.86; ⁤*P = 0.0007)
* Myocardial Infarction: HR 0.86 (95% CI, ‍0.79-0.95; P* = 0.0147)
* Non-Significant Reductions: ⁣ While trends were observed, reductions in cardiovascular death (HR 0.44; *P = 0.1528) and ‍ischemic stroke (HR 0.83; P* = 0.1856) were not statistically significant.
* Importance of Adherence: The authors emphasize‍ the importance of both adherence *and persistence with LLTs in secondary prevention to reduce the risk of death and recurrent cardiovascular events.

Implications:

The findings ⁣provide valuable information for physicians⁤ managing high-risk patients, potentially guiding‍ clinical decision-making and optimizing patient care to improve LLT adherence.

Reference:

Jones LK,East⁣ C,Ganda OP,Gionfriddo MR. Adherence to Lipid-Lowering Therapies and cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025;14(17):e037530. doi:10.1161/JAHA.124.037530